Data Summary {#s1-2}
============

1\. All raw genome sequences, including Illumina paired-end short reads and Oxford Nanopore long reads, have been deposited in the SRA (Sequence Read Archive) under project number PRJNA396979. Individual accession numbers for each strain are provided in Table S1 (available with the online version of this paper).

2\. The annotated genome assembly for strain A2, the reference genome for the founder genotype, has been submitted to GenBank under accession number CP024124 (chromosome) and number CP024125 (plasmid).

3\. Hybrid assemblies for strains A1, A3, A8, A13, A15, A17 and A20 are available in FigShare, [https://doi.org/](https://doi.org/10.4225/49/5987e14e9b530)10.4225/49/5987e14e9b530 (note they were not deposited in GenBank as they differ from A2 by only 1--4 single nucleotide polymorphisms as indicated).

###### Impact Statement

*Acinetobacter baumannii* is a highly drug-resistant pathogen that is frequently found within intensive care units (ICUs) and especially impacts patients with severe burns. While several studies have examined the global population structure of *A. baumannii*, few have investigated within-host evolution of *A. baumannii* in direct response to antibiotic treatment in a single patient. Here, we analysed the genetic evolution of *A. baumannii* isolated from a patient with severe burns over the course of their stay in an ICU. The *A. baumannii* population on this patient was highly drug resistant, carrying two distinct genomic islands encoding resistance to several antibiotics, but not carbapenems. The bacterial population comprised four distinct subclades, two of which had evolved carbapenem resistance over the course of the antibiotic treatment through novel mutations in genes associated with drug binding. One subclade was also transmitted to another patient on the ward. While carbapenem resistance is common in *A. baumannii*, this is generally attributed to horizontally transferred carbapenemase genes. These data provide evidence for carbapenem resistance arising *in vivo* via non-synonymous substitutions during a single infection episode, demonstrating carbapenem resistance can emerge in genetic isolation in response to exposure to carbapenems and other drugs.

Introduction {#s1-4}
============

*Acinetobacter baumannii* is a Gram-negative bacterium that is amongst the six most common causes of multidrug resistant (MDR) hospital-acquired infections, a group collectively known as ESKAPE pathogens \[[@R1]\]. *A. baumannii* is a common causative agent of pneumonia, bacteraemia, urinary tract infections, meningitis and wound infections, especially in burns patients \[[@R2]\]. *A. baumannii* is intrinsically resistant to a broad range of antibiotics; however, over the last three decades additional acquired resistance has emerged \[[@R3]\]. Acquired resistance to first-line antibiotics, including aminoglycosides, sulfonamides and tetracycline, arose in the 1970s, with most resistance genes residing on the chromosome within the resistance island AbaR, acquired independently by each *A. baumannii* lineage \[[@R4]\]. During the 1980s and 1990s, resistance to third-generation cephalosporins and fluoroquinolones emerged. Upregulation of the chromosomal β-lactamase-encoding gene *ampC*, by ISAba1 or ISAba125, is the primary mechanism of cephalosporin resistance \[[@R10]\]. Fluoroquinolone resistance is primarily mediated through non-synonymous mutations in *gyrA* and *parC,* which interfere with drug binding \[[@R13]\]. Carbapenem resistance is becoming increasingly common, mainly through the acquisition of carbapenem-hydrolysing oxacillinase genes \[[@R3]\]. Carbapenem resistance has also been associated with changes in the expression of penicillin-binding proteins \[[@R16]\] or the AdeABC efflux pump \[[@R17]\], which can also impact resistance to other drugs, such as fluoroquinolones \[[@R19]\]. The prevalence of carbapenem resistance in *A. baumannii* leaves only polymyxins (such as colistin) and tigecycline available for treatment. Resistance to these drugs has already been observed \[[@R3]\], and in 2017 the World Health Organization named carbapenem-resistant *A. baumannii* as the top priority pathogen critically requiring research and development of new antibiotics \[[@R23]\].

The *A. baumannii* population primarily responsible for hospital infections in humans largely consists of two globally distributed clones, GC1 and GC2 \[[@R24]\]. Previous studies have begun to untangle the evolution of these clones \[[@R7]\], including the evolution of sub-clones specific to a particular hospital \[[@R25]\]. However, very few studies have investigated evolution of *A. baumannii* within individual patients. Within-host evolution has been studied in several other pathogens, including *Staphylococcus aureus*, *Helicobacter pylori* and *Burkholderia pseudomallei* \[[@R26]\]. One study retrospectively investigated within-host evolution of *A. baumannii* in patients from a single hospital system, revealing enrichment for mutations in genes responsible for antibiotic resistance or immune responses, with the *pmrAB* genes (linked to colistin resistance) being the most commonly mutated \[[@R29]\]. In addition, the regulatory genes *adeRS*, responsible for regulating the efflux pump AdeABC, were also found to be commonly mutated \[[@R29]\]. Another study compared the genomes of *A. baumannii* isolated from two patients pre-treatment (sensitive) and post-treatment (resistant) with polymyxin B, and identified non-synonymous mutations in the *pmrB* gene in both cases (one GC1 and one GC2) \[[@R30]\]. These studies demonstrate mechanisms by which *A. baumannii* can adapt rapidly under positive selection from antimicrobial exposure during therapy with polymyxins. However, as both studies only examined pairs of isolates from each patient, they were unable to examine the diversification of the pathogen population during prolonged infection. Furthermore, while we have previously used genomics to unravel the mechanisms of evolution of carbapenem resistance at the level of an intensive care unit (ICU) \[[@R25]\], there are no published studies reporting within-host evolution of carbapenem resistance during an individual infection.

In this case study, we investigate the evolution of an *A. baumannii* strain within a single ICU patient, who had extensive burn wounds and developed a prolonged MDR *A. baumannii* infection. Treatment of this infection was complicated by the presence of resistance to most available drugs at the onset, followed by the emergence of resistance to meropenem after its therapeutic use. Here, we compared the genomes of 20 isolates cultured from serial samples of burn wound sites at nine time points spanning 68 days, including multiple samples taken at the same time from different body sites. We identified two distinct subpopulations of meropenem-resistant strains harbouring non-synonymous substitutions in *adeB* and/or *ftsI*, and used structural modelling of the encoded proteins to demonstrate that these mutations can explain the observed loss of meropenem susceptibility.

Methods {#s1-5}
=======

Bacterial isolates and antimicrobial-susceptibility profiling {#s2-5-1}
-------------------------------------------------------------

All *A. baumannii* strains cultured from burn wound sites during the clinical care of a patient at The Alfred Hospital, Melbourne, Australia, were included (*n*=20). Single isolates from three other patients, who were cared for in the same ward and during the same time as our index patient, were also included. All bacterial isolates underwent susceptibility testing using automated methods (VITEK2), with confirmation of meropenem susceptibility and determination of MICs by Etest as per the manufacturers guidelines (bioMérieux).

DNA extraction and sequencing {#s2-5-2}
-----------------------------

*A. baumannii* isolates were grown in Luria broth (LB) overnight at 37 °C with shaking. For the extraction of genomic DNA, we first generated cell lysates using a Bacterial GenElute kit (Sigma) according to the manufacturer's instructions for Gram-negative bacteria preparation. Cell lysates were then cleaned using the Qiagen DNeasy kit according to the manufacturer's instructions and DNA was eluted in nuclease-free water. DNA sequencing libraries were prepared used the Nextera XT protocol, and 100 bp paired-end sequencing was performed on each sample using the Illumina HiSeq 2500 at the Australian Genome Research Facility (Melbourne, Australia). Mean insert size for each genome was 445 bp, with a mean read depth of 121× (Table S1, available in the online Supplementary Material). All reads were deposited in the SRA (Sequence Read Archive) under the accession numbers listed in Table S1.

For long-read sequencing, each isolate was grown overnight at 37 °C on LB plates, and then single colonies were grown overnight at 37 °C in LB. Bacterial cell pellets from 3.0 ml broth culture were generated by centrifugation at 15 000 ***g*** for 5 min. DNA was extracted from these pellets using Agencourt GenFind V2 (Beckman Coulter) with minor modifications, as described in \[[@R31]\]. No further purification or size selection is required, as this protocol generates high molecular weight genomic DNA that is free of small DNA contamination. Oxford Nanopore Technologies (ONT) sequencing libraries were prepared without shearing to maximize read length. Adapters were ligated to each library using the Nanopore 1D ligation sequencing kit (SQK-LSK108) with the native barcoding expansion kit (EXP-NBD103) and modifications as described in \[[@R31]\]. The resulting library contained 3530 ng DNA and was loaded onto an R9.4 flow cell. A MinION MK1b device (ONT) was used to perform the run using the NC_48 h_Sequencing_Run_FLO-MIN106_SQK-LSK108 protocol, with 910 pore numbers available. At the completion of the run, all resulting [fast]{.smallcaps}5 files were transferred to a separate Linux server, where bases were called using ONT\'s Albacore command line tool (v1.0.1), using barcode demultiplexing and [fastq]{.smallcaps} output. Adapter sequences were trimmed from the reads using Porechop (v0.2.0, <https://github.com/rrwick/Porechop>), with barcode demultiplexing, and only keeping reads where Albacore and Porechop agreed on the barcode bin, to prevent cross-barcode contamination. The mean read length was 9148 bp and the mean read depth per isolate was 59× (Table S1). The resulting demultiplexed, barcode trimmed reads were deposited in the SRA (Sequence Read Archive) under the accession numbers listed in Table S1.

Whole-genome assembly {#s2-5-3}
---------------------

For the eight isolates for which both long (ONT) and short (Illumina) reads were generated, hybrid *de novo* assemblies were constructed using Unicycler v0.3.1 \[[@R32]\] with default settings. This resulted in complete assemblies with two circular replicons (one chromosome and one plasmid) for isolates A1, A2, A8, A13, A15, A17 and A20, and a single circular replicon (one chromosome) for isolate A3. For the remaining isolates, for which only Illumina-based short reads were available, *de novo* assemblies were generated using SPAdes v3.6.1 \[[@R33]\] with the kmer sizes parameter set to 21, 33, 45, 57, 69, 81 and 93. All genome sequences (complete and draft) were annotated with [rast]{.smallcaps} using default settings \[[@R34]\].

Detection of resistance genes and multi-locus sequence type (MLST) {#s2-5-4}
------------------------------------------------------------------

Raw sequence reads were screened using [srst2]{.smallcaps} v0.2.0 \[[@R35]\] to identify (i) antibiotic-resistance genes using the [arg]{.smallcaps}-[annot]{.smallcaps} database \[[@R36]\] and (ii) MLST using the Institut Pasteur *A. baumannii* MLST scheme. Assemblies were also screened for antibiotic-resistance genes using [blast]{.smallcaps}+ v2.6.0 \[[@R37]\], in order to determine the genetic context of resistance genes. Regions containing resistance genes were extracted from the assemblies and compared with known resistance islands in *A. baumannii* using [blast]{.smallcaps}+, and the comparisons visualized using [act]{.smallcaps} \[[@R38]\].

Detection of variation between isolate genomes {#s2-5-5}
----------------------------------------------

### Single nucleotide polymorphism (SNP) detection {#s3-5-5-1}

All isolates were mapped to the completed A2 genome (i.e. the first strain isolated from the index patient) using RedDog v1beta10.3 (<https://github.com/katholt/RedDog>) with default parameters. Briefly, Illumina reads were mapped using Bowtie2 v2.2.9 \[[@R39]\] using the sensitive-local algorithm and a maximum insert length of 2000 (set with the *x* parameter). Variant sites (SNPs and indels) were called using SAMtools v1.3.1 \[[@R40]\]. Isolate A22 was identified as an outgroup, with only 87 % coverage of the reference genome (compared to ≥99 % for all other genomes). This isolate contained 103 519 SNPs, and was a different sequence type (ST) to the other strains, so was excluded from further analysis. Amongst the remaining 22 isolates, a total of 12 SNPs was identified.

### Insertion sequence (IS) variation {#s3-5-5-2}

ISsaga \[[@R41]\] was used to screen the A2 genome sequence for all known ISs. ISs detected in the chromosome were ISAba22, IS26, ISVsa3, ISAba26, IS1326 and ISAba1. ISMapper \[[@R42]\] was used to screen all Illumina read sets for evidence of variation in copy number and location of the six ISs in the other 21 genomes, in comparison to the A2 reference genome. The depth cut-off was set to ≥20× (rather than the default value, ≥6×) to avoid spurious calls in these deeply sequenced genomes (87--149×). Visual inspection of all ISAba1 hits in all genomes was also undertaken to confirm the exact location and orientation of each insertion site. The ISMapper results were compared to the eight finished genome assemblies belonging to the main clone, and were found to be in complete agreement concerning the position of all IS insertions.

### Pairwise comparison of completed genomes {#s3-5-5-3}

The eight completed, hybrid genome assemblies were subjected to pairwise base-by-base comparison using the *diffseq* function in the [emboss]{.smallcaps} package \[[@R43]\]. This analysis confirmed all SNPs and indels detected by RedDog, the ISAba1 variation detected by ISMapper, and additionally identified: the loss of two tRNA genes within A2, the loss of a 52 kbp phage region in A8, an additional 1 bp intergenic insertion in A18 and A20, and a 1 bp insertion within Bm3R1 in A2, relative to all other genomes.

Structural modelling of mutations in AdeB and FtsI associated with meropenem resistance {#s2-5-6}
---------------------------------------------------------------------------------------

Molecular models of AdeB and FtsI were generated using Modeller \[[@R44]\] and Macro Model (Schrodinger) using the X-ray crystal structures of homologous membrane pumps (PDB IDs: 1OY8, 2V50 and 4MT1; sequence identity 45--60 %) and related penicillin-binding proteins (PDB IDs: 3EQU, 3OC2, 3PBQ, 3PBN, 3UE3, 4BPJ and 5ENS; sequence identity 43--87 %), respectively. The models were then minimized using the MMF94s forcefield in Sybyl-X 2.1.1 (Certara), with the final structures having more than 95 % of residues in the allowed region of a Ramachandran plot. Meropenem was docked into the models using Glide (Schrodinger), and the position of the ligands in available crystal structures used to guide placement. The quality of the models was confirmed with Verify3D (data not shown). Model structures were examined using Arpeggio \[[@R45]\] and PyMOL.

The structural consequences of the missense variants were analysed to account for all the potential effects of the mutations \[[@R46]\]. The effects of the mutations upon the stability of the proteins was predicted using [sdm]{.smallcaps} \[[@R47]\], mCSM-Stability \[[@R48]\] and [duet]{.smallcaps} \[[@R49]\]. The effect of the mutations upon the binding affinity for meropenem were predicted using mCSM-Lig \[[@R50]\]. These computational approaches represent the wild-type residues structural and chemical environment of a residue as a graph-based signature in order to determine the change upon mutation in Gibb's free energy of stability or binding.

Presence of mutations in AdeB and FtsI in other *A. baumannii* genomes {#s2-5-7}
----------------------------------------------------------------------

To determine whether the meropenem-resistance-associated alleles were present in other *A. baumannii* genomes, the protein sequences for these alleles were extracted and compared to all *A. baumannii* genomes currently in the National Center for Biotechnology Information (NCBI) database as of February 11 2018, using [tblastn]{.smallcaps}.

Results {#s1-6}
=======

During a 3 month period in 2013, 20 MDR *A. baumannii* isolates (A2--A20, A22) were cultured from swabs collected from the burn wound sites of a single patient (patient 1) with extensive burns, who was being treated in the ICU of a tertiary care hospital in Melbourne, Australia. The *A. baumannii* were isolated from swabs taken from several different sites across the body, sampled at nine time points ([Figs 1b](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}). Three additional *A. baumannii* isolates, cultured from wound swabs from three other patients admitted to the same ICU ward within a month of patient 1\'s stay, were included in the study for comparison. These were A1 (patient 0, isolated 2 days prior to patient 1\'s first isolate), A21 (patient 2, 9 days after A20) and A23 (patient 3, 59 days after A20).

![Population structure of *A. baumannii* and sample locations. (a) Minimum spanning tree illustrating the population structure of all isolates, based on all genome variation detected. Circles indicate isolates whose genomes are genetically identical, with circle size relative to the number of isolates. Circles are coloured to indicate the subclades referred to in the text; grey circles indicate isolates from other patients. Annotations above connecting lines indicate genome variation detected; non-synonymous SNPs (nsSNPs) in protein-encoding genes are labelled with the effect on the amino acid sequence; synonymous SNPs (sSNPs) and intergenic SNPs are enumerated. Outlines around circles are indicative of meropenem MIC: no outline, MIC\<8 µg ml^−1^; thin outline, MIC≥8 µg ml^−1^; thick outline, MIC≥32 µg ml^−1^. (b) Body map showing swab locations for samples of each lineage collected from patient 1. Light grey with glasses, front of patient; dark grey, back of patient. Isolates are numbered in the order the swabs were collected. Circle outlines indicate meropenem resistance, as in (a). L, Left; R, right.](mgen-4-165-g001){#F1}

![Infection timeline for patient 1. (a) Bar chart illustrating meropenem MIC for each isolate, with timeline below showing sample collection dates (relative to day 0=first isolation from patient 1). Bars are coloured by the genetic subclade, as defined in [Fig. 1(a](#F1){ref-type="fig"}). The dashed red line shows MIC=8 µg ml^−1^, the EUCAST (European Committee on Antimicrobial Susceptibility Testing) threshold for defining resistance. (b) Temporal map of mutations identified in each isolate\'s genome, coloured by subclade. Orange circles indicate the dates on which the founder genotype was isolated; all genetic variation in other isolates are shown relative to this founder genotype. The delta symbol indicates deletion. (c) Timeline of antibiotic treatment. Coloured bars show the length of time patient 1 was treated with each antibiotic during their stay in the ICU. Antibiotic dosing was as follows: piperacillin/tazobactam, 4.5 g intravenously three times per day; vancomycin, 1 g intravenously twice per day; ciprofloxacin, 400 mg intravenously three times per day; meropenem, 1 g intravenously (increasing to 2 g from day 28) three times per day; colistin, 150 mg intravenously twice per day.](mgen-4-165-g002){#F2}

All 23 *A. baumannii* isolates were sequenced using the Illumina platform. MLST and SNP analysis indicated that 22 of the isolates were GC2 (ST 2 according to the Institut Pasteur 7-locus MLST scheme) and formed a single clonal lineage with a maximum pairwise distance of eight SNPs ([Fig. 1a](#F1){ref-type="fig"}). A22 was a distinct strain of *A. baumannii*, separated from the main clonal lineage by \>100 000 SNPs and belonged to a novel ST. This was the final isolate from patient 1, cultured 3 weeks after the last GC2 isolate, and likely represents secondary infection with a novel strain.

Variation amongst the 22 clonal isolates {#s2-6-1}
----------------------------------------

The complete annotated genome sequence of strain A2, the first isolate cultured from patient 1, was used as a reference for detailed comparative analyses. A total of 12 SNPs was detected amongst the 22 clonal GC2 isolates (9/12 non-synonymous, 2/12 synonymous, 1/12 intergenic; [Figs 1a](#F1){ref-type="fig"} and [2c](#F2){ref-type="fig"}). All isolates except A3 carried identical copies of the 110 kbp plasmid, confirmed by read mapping and assembly. Six different ISs were present in the chromosome of A2, at a total of 37 unique sites: ISAba1 (23 sites), IS*26* (8 sites), ISAba22 (3 sites), ISAba26 (1 site), ISVsa3 (1 site) and IS*1326* (1 site). All but one of the IS insertions present in A2 were conserved across all isolates. The exception was a single ISAba1 insertion between two genes encoding hypothetical proteins (coordinates 1 871 431--1 872 182 in A2), which was absent in A1 but present in all other genomes. Notably A1 was the first strain isolated, from patient 0, 2 days prior to Patient 1\'s first isolate and, therefore, was considered the index case.

To facilitate high-resolution analysis of intra-host evolution, eight of the clonal GC2 isolates from patient 1, and the index case from patient 0, that displayed distinct genotypes and AMR phenotypes (strains A1, A2, A3, A5, A8, A15, A17 and A20) were selected for long-read sequencing. The combined short- and long-read sequence data were used to assemble complete genomes for each of these isolates, which each consisted of a 3.9 Mbp chromosome and identical copies of a 110 kbp plasmid (with the exception of A3, which lacked any evidence of plasmid sequence in short or long reads). Comparison of the completed genomes to sequences in GenBank via [blast]{.smallcaps} searches revealed that the chromosome was most closely related to *A. baumannii* GC2 strain XH856 (isolated in 2010 in China; accession no. CP014541, 99 % identity and 95 % coverage), and the plasmid was similar to the previously described plasmid pABTJ2 (accession no. CP004359, 99 % identity and 100 % coverage) sequenced from *A. baumannii* GC2 strain MDR-TJ (isolated in China, year not reported) \[[@R53]\].

Base-by-base comparison between the eight finished genomes confirmed the SNP and IS variation data inferred from short reads, and additionally detected a single base pair intergenic insertion in A18 and A20, a single base pair insertion in Bm3R1 (a helix-turn-helix transcriptional repressor) in A2, the loss of two adjacent tRNA genes (tRNA-Trp and tRNA-Leu) from A2, and the loss of a 52 kbp phage region in A8 ([Figs 1a](#F1){ref-type="fig"} and [2b](#F2){ref-type="fig"}).

Nearly half (9/19) of the clonal isolates from patient 1 formed a group of genetically indistinguishable strains (orange, [Fig. 1a](#F1){ref-type="fig"}) that were isolated from multiple body sites between days 4 and 28 ([Figs 1b](#F1){ref-type="fig"} and [2a](#F2){ref-type="fig"}). This dominant genotype occupied a centroid position in the minimum spanning tree of all strains from patient 1, suggesting it likely represents the founder genotype in this patient. The isolates from the three other ICU patients, which were collected within 1 month before or after patient 1\'s infection, all belonged to the same clone and differed from the founder genotype by no more than one SNP ([Fig. 1a](#F1){ref-type="fig"}).

The remaining isolates from patient 1 formed four related subclades, each characterized by a unique set of differences from the founder genotype. Subclade A (*n*=3, green, [Fig. 1](#F1){ref-type="fig"}) was characterized by a single SNP and detected only on swabs taken from the left buttock and right anterior thigh area, early on in the series (day 4--21). Subclade B (*n*=2, blue, [Fig. 1](#F1){ref-type="fig"}) was detected on the left upper back and left flank in the middle of the series (day 13, day 23). Subclade C (*n*=4, purple, [Fig. 1](#F1){ref-type="fig"}) emerged via a stepwise series of mutations that accumulated later in the series. The initial SNP was first detected on the left trunk (day 21), and strains sharing this SNP plus additional mutations were subsequently detected on the right trunk (day 28), back (day 34) and right arm (day 45). The fourth subclade (D) was represented by a single isolate, A2, cultured from the right medial thigh on day 0.

To explore the rate of within-host evolution occurring during the prolonged infection of patient 1, we calculated for each isolate: (*x*) the temporal distance (in days) since the first detection of the clone in the patient (day 0), and (*y*) the genetic distance (in single base pair mutations) from the founder genotype; and fit a linear regression of *y* on *x* (*P*=0.0009, *R*^2^=0.49). The fitted slope was 0.065, corresponding to a rate of \~1 mutation per 15 days (\~24 mutations per year). As expected, this intra-host mutation rate is several fold higher than genome-wide substitution rates estimated for *A. baumannii* spreading between hosts over several years (\~10 substitutions per year for GC2 and \~5 substitutions per year in GC1 \[[@R7]\]), which are affected by purifying selection and evolutionary bottlenecks associated with transmission to new hosts.

Evolution of antibiotic resistance {#s2-6-2}
----------------------------------

All *A. baumannii* isolates cultured from patient 1 were MDR, displaying resistance to aminoglycosides, fluoroquinolones, trimethoprim/sulfamethoxazole, third- and fourth-generation cephalosporins (ceftazidime and cefepime), and carboxypenicillins. Variation was observed in sensitivity to meropenem (a carbapenem) (see [Fig. 2](#F2){ref-type="fig"} and detailed below).

All antibiotic-resistance phenotypes besides meropenem could be explained by acquired resistance genes that were conserved in all the clonal (GC2) genomes. A variant of the AbGRI1-1 genomic island was present within the *comM* gene \[[@R54]\], encoding resistance to streptomycin (*strAB*), sulfonamides (*sul2*) and tetracyclines \[*tetB, tetR(A)*\]. A variant of the resistance island AbGRI2-0 was also present \[[@R55]\]. This second resistance island included a partial mercury resistance operon (*mer*), and resistance genes for aminoglycosides (*aph3′′Ia, aadA1, aac3-I*), sulfonamides (*sul1*) and ampicillin (*bla*~TEM-1~). In addition to acquired resistance genes, all isolates also harboured an ISAba1 insertion site upstream of the intrinsic efflux pump *ampC*, which is known to generate resistance to third-generation cephalosporins \[[@R10]\]. The *bla~OXA~*~-66~ gene was also present within the chromosome. While the encoded Oxa-66 protein can have intrinsic carbapenemase activity, upregulation via IS elements or structural changes via non-synonymous mutations within the protein are required for full carbapenem resistance, neither of which were identified in these genomes (and all had identical *bla~OXA~*~-66~ gene sequences and promoter regions).

The majority of isolates, including all with the founder genotype (orange, [Figs 1 and 2](#F1 F2){ref-type="fig"}), displayed meropenem MIC≤4 µg ml^−1^ (Table S1). Reduced sensitivity to meropenem was first observed in subclade A, which differed from the founder genotype by a non-synonymous substitution (G288S) in AdeB (green, [Figs 1 and 2](#F1 F2){ref-type="fig"}). These isolates displayed an increased MIC for meropenem (≥8 µg ml^−1^). Subclade C isolates also displayed increased meropenem MICs and carried a different substitution (F136L) in AdeB (purple, [Figs 1 and 2](#F1 F2){ref-type="fig"}). Isolate A12 differed from the founder genotype by this SNP alone, and displayed an MIC of 8 µg ml^−1^. The later isolates A18, A19 and A20 (days 28, 34 and 45, see [Figs 1 and 2](#F1 F2){ref-type="fig"}) carried the AdeB F136L mutation and an additional substitution in the penicillin-binding protein (PBP3) FtsI (A515V), and displayed high-level resistance to meropenem (MIC≥32 µg ml^−1^).

The schedule of antimicrobial therapy supplied to patient 1 is shown in [Fig. 2(c](#F2){ref-type="fig"}) and included two courses of meropenem. The meropenem-resistant subclade A emerged prior to the initiation of meropenem treatment and persisted after its completion; this is potentially because the AdeB efflux pump can also transfer ciprofloxacin \[[@R19]\] to which the patient had been exposed prior to first detection of any AdeB mutations ([Fig. 2](#F2){ref-type="fig"}). The first meropenem-resistant subclade C isolate, A12, was also collected after the completion of the first course of meropenem. However, three meropenem-sensitive isolates (A14, A15 and A16) were subsequently recovered, and a second course of meropenem treatment was initiated. A few days later, a subclade C isolate (A18) with the additional *ftsI* mutation and high-level meropenem resistance (MIC\>32 µg ml^−1^) was recovered, prompting the introduction of colistin for treatment, with subsequent resolution of infection.

Structural basis for meropenem resistance {#s2-6-3}
-----------------------------------------

It is striking that both subclades displaying increased MICs for meropenem carried non-synonymous mutations in the same protein, AdeB. The AdeABC efflux pump system has previously been implicated in carbapenem resistance, through the upregulation of the trans-membrane protein AdeB \[[@R3]\]. Here, we observed resistance (MIC≥8 µg ml^−1^) in all strains carrying either a G288S (subclade A, green) or an F136L (subclade C, purple) mutation in AdeB. Structural modelling of AdeB (see Methods) showed that the residues affected by these two mutations are located within the intracellular domain of the protein, which is responsible for the recognition of compounds to be passed to the outer membrane protein AdeC. Both mutations were within 5 Å of the bound meropenem in the model ([Fig. 3a](#F3){ref-type="fig"}). Both mutations were predicted to mildly destabilize the local structure \[ΔΔG~Stability~^G288S^=−0.62±0.15 kcal mol^−1^ (−2.59±0.63 kJ mol^−1^) and ΔΔG~Stability~^F136L^=−0.91±0.14 kcal mol^−1^ (−3.81±0.59 kJ mol^−1^)\], opening the drug binding site and pore, allowing meropenem to be more effectively exported. Neither of these two AdeB mutations were found in any publicly available *A. baumannii* genome in the NCBI database at the time of writing.

![Meropenem bound to AdeB and FtsI. (a) AdeB. The substitutions G288S (subclade A, green sticks) and F136L (subclade C, purple sticks) are predicted to facilitate binding and export of meropenem, shown here as the orange molecule. (b) FtsI. The substitution A515V (magenta sticks) is located in close proximity to the binding site for meropenem (orange molecule), and is predicted to increase the binding affinity and sequestration of the drug. Other variants G523V and H370Y (green sticks), previously observed in carbapenem-sensitive strains, are predicted to either reduce or have little effect on the binding affinity.](mgen-4-165-g003){#F3}

High-level resistance (MIC≥32 µg ml^−1^) was observed only in the three subclade C strains that carried the FtsI A515V mutation in addition to AdeB-F136L. Examination of other *A. baumannii* genomes in the NCBI database revealed that eight genomes (CP014291, CP017646, CP017642, CP014538, CP007535, CP007577, CP006963 and CP001921) contained the FtsI A515 mutation, without the corresponding AdeB G288S or AdeB F136L mutations. FtsI is a class B penicillin-binding protein, associated with cell division \[[@R58]\]. Two mutations (G523V, H370Y) have been reported previously in this protein, but they showed no evidence of contributing to carbapenem resistance \[[@R58]\]. Here, we modelled these mutations and the A515V mutation present in our meropenem-resistant isolates. The G523V mutation is located approximately 9 Å away from the meropenem binding site, and was predicted to greatly destabilize drug binding \[−2.6±0.05 log~10~ (fold change in affinity)\]. By contrast, H370Y is located quite distal from the binding site (20 Å) and is predicted to have minimal effect on the affinity for meropenem \[−0.03±0.08 log~10~ (fold change in affinity)\]. In our data, the mutation A515V is located close (7 Å) to the drug binding site of the protein ([Fig. 3b](#F3){ref-type="fig"}). Structural modelling indicated that mutation to valine would be well tolerated \[mildly stabilizing, ΔΔG~Stability~=0.25 kcal mol^−1^ (1.05 kJ mol^−1^)\] and lead to a significant increase in the binding affinity for meropenem \[0.16±0.04 log~10~ (fold change in affinity)\], explaining the reduced effectiveness of meropenem against these strains.

Discussion {#s1-7}
==========

Here, we showed that the prolonged infection of patient 1 was primarily due to spread of a founding *A. baumannii* genotype, most likely acquired from patient 0. Over the course of antibiotic treatment in patient 1, the *A. baumannii* population diversified into three distinct subclades that were associated with time periods and specific spatial zones on the body of patient 1, in addition to onward transmission to two other patients on the ward. During the evolution of this infection, two meropenem-resistant lineages (MIC≥ 8 µg ml^−1^) emerged via non-synonymous substitutions in AdeB, with further increase in MIC (≥32 µg ml^−1^) due to a non-synonymous substitution in FtsI. The majority of resistance to meropenem and other carbapenems in *A. baumannii* is due to acquisition of carbapenemases via horizontal gene transfer; indeed prior to this study, the upregulation of the AdeABC efflux pump was the only other known mechanism of meropenem resistance in *A. baumannii* \[[@R3]\]. In this study, we were able to reliably detect indel variation with long-read sequencing data, and found that indels were not responsible for the resistance phenotype observed. However, whilst this long-read data was not crucial to our analysis, in future studies it may be required to provide better resolution.

Previous studies investigating *A. baumannii* evolution over short time periods have mostly focused on several patients within the same hospital system, with only a few samples taken per patient \[[@R29]\]. These studies indicated that reinfection with novel strains often occurred after treatment \[[@R61]\]. In our patient, only a single isolate taken at the very end of the series was a completely novel strain, diverged from the founder genotype by over 100 000 SNPs. The presence of this novel strain occurred 3 weeks after the core group of strains and following apparent resolution of the infection, and may have arisen due to treatment with colistin eradicating the founding strain population. However, at later time points, only single swabs were taken, and so this potentially underestimates the diversity of the population beyond the final course of antibiotic treatment.

These data highlight the therapeutic risks involved with treating high-burden *A. baumannii* infections, especially in the context of prolonged and severe burn wounds. The phenotype--genotype relationships also highlight the importance of antibiotic selection pressure being able to drive resistance not only to the agent being used, but also to other antibiotics through shared resistance mechanisms. For example, the study suggests the activity of multidrug efflux pumps such as AdeABC may be increased through exposure to quinolones, with subsequent effects on meropenem susceptibility. However, the lack of the AdeB mutations found in this study in other strains indicates that there is likely a fitness cost to meropenem resistance acquired in this way, likely more so than meropenem resistance acquired through the gain of a carbapenemase-resistance gene or efflux pump upregulation. The various subclades were identified at several burn wound infection sites, representing the ease at which bacteria on wounds and the skin can infect neighbouring sites. The mechanisms of how bacteria seed regions of skin are multifactorial, from simply contacting bedding surfaces and then re-seeding neighbouring areas of skin, to more complex aspects of bacterial proliferation along the skin surface itself or the wound dressings \[[@R62]\].

The patient history also highlights the importance of cumulative mutations that can ensue after recurrent antibiotic exposures, culminating in extreme drug resistance, which supports the practice of taking into account prior antibiotic exposures when deciding on new empiric treatment of recurrent burn wound infections. However, while clinicians are aware of the potential for resistance to emerge, this must be balanced against the need to choose the narrowest spectrum antibiotic they can to achieve optimal therapy with minimal toxicity, particularly in the context of a non-life-threatening burn wound infection. In this case, the appearance of meropenem-resistant strains prompted withdrawal of meropenem therapy. Ten days later, three infecting strains were then meropenem susceptible, so meropenem therapy was resumed. However, the apparent reversion to a susceptible phenotype turned out to be masking the persistence of a resistant subpopulation, which resurged following the resumption of meropenem and prompted escalation to colistin and ultimately resolution of the infection. This exemplifies the rapid and efficient ability of *A. baumannii* to genetically adapt to antibiotic selection pressures, both upregulating and downregulating resistance in response to changes in antibiotic-treatment regimens; and highlights both the need to consider the potential for heterogeneity in intra-host pathogen populations, and the importance of regular monitoring of cultures and symptoms for signs of emerging resistance to guide active antibiotic treatment.
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